Suramin for Recluse Spider Bites

Suramin for Recluse Spider Bites：SpiderTek，一家开发出第一个蜘蛛叮咬的生物技术公司 诊断测试，建议使用苏拉明治疗由于Loxoscelesthre erecclulseusspiade，r， 非洲昏睡病的百年疗法美国中南部人口8000万 和隐居蜘蛛住在一起每年，估计有30，000人遭受隐士蜘蛛咬伤， 导致疼痛，缓慢愈合的伤口。每年有数百名患者发生溶血， 严重，尤其是儿童和老年人。美国的治疗仅限于支持性的 措施现在有了准确的诊断，下一步就是开发有效的治疗方法。我们 基于苏拉明分子与磷脂酶D结合的发现提出了一种治疗方案， 隐士蜘蛛毒液中的活性成分 这项研究的总体目标是为这些蜘蛛咬伤开发一种优化的治疗方法。相 我将确定苏拉明治疗loxoscelism的治疗限制。首先，我们将确定范围 体内有效剂量的变化。接下来，我们将确定有效的时间窗口， 治疗-咬伤后多久进行治疗才有效？最后，我们将比较 苏拉明注射液与一种新的局部给药技术，这将使患者避免紧急情况 房间参观拟议的研究将为我们提出的苏拉明治疗提供基本的概念验证， 使我们能够在计划的II期研究中开展人体试验。 最后，我们的跨学科研究团队涉及私营SpiderTek和 密苏里州大学。这两个实体都位于密苏里州农村，那里的loxoscelism发病率很高。 该团队具有多学科的专业知识，包括动物科学家，第一个基于ELISA的 牛怀孕测试以及我们的蜘蛛咬伤诊断测试，皮肤科医生具有丰富的经验， 隐士蜘蛛叮咬，和一个广泛认可的开发商的局部制剂。与以往成功的 将第一个蜘蛛咬测试推向市场的经验，以及与 首席研究员和他的同事，该小组是独特的定位，以执行拟议的研究。

Suramin for Recluse Spider Bites: SpiderTek, a biotechnology company that developed the first spider bite diagnostic test, proposes therapy for bites due to Loxoscelesthre erecclulseusspiade,r, using suramin, a century-old treatment for African sleeping sickness. A population of 80 million in the South-Central US shares homes with the recluse spider. Each year, an estimated 30,000 persons suffer recluse spider bites that can result in painful, slowly healing wounds. Hundreds of patients annually develop hemolysis, which can be severe, especially in children and older persons. Therapy in the United States is limited to supportive measures. With accurate diagnosis now available, the next step is to develop an effective treatment. We propose a therapeutic solution based on the discovery that the suramin molecule binds to phospholipase D, the active component in the recluse spider venom. The overall objective of the proposed research is to develop an optimized therapy for these spider bites. Phase I will determine the therapeutic constraints of suramin therapy in loxoscelism. First, we will determine the range of the effective in-vivo dose as we vary suramin dose. Next, we will determine the time window for effective treatment—how soon after the bite does treatment have to occur to be effective? Finally, we will compare suramin injection with a novel topical administration technique, which will enable patients to avoid emergency room visits. The proposed research will provide basic proof-of-concept for our proposed suramin therapy for loxoscelism and enable us to develop a human trial in planned Phase II research. Finally, our interdisciplinary research team involves collaboration between privately held SpiderTek and the University of Missouri. Both entities are located in rural Missouri, where the incidence of loxoscelism is high. The team features multidisciplinary expertise, including an animal scientist, developer of the first ELISA-based pregnancy test for cattle as well as our spider bite diagnostic test, a dermatologist with extensive experience in recluse spider bites, and a widely recognized developer of topical formulations. With previous successful experience in bringing the first spider bite test to market and with strong existing collaborations between the principal investigator and his colleagues, the team is uniquely positioned to perform the proposed research.